MX2023010430A - Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). - Google Patents
Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).Info
- Publication number
- MX2023010430A MX2023010430A MX2023010430A MX2023010430A MX2023010430A MX 2023010430 A MX2023010430 A MX 2023010430A MX 2023010430 A MX2023010430 A MX 2023010430A MX 2023010430 A MX2023010430 A MX 2023010430A MX 2023010430 A MX2023010430 A MX 2023010430A
- Authority
- MX
- Mexico
- Prior art keywords
- kras
- inhibitors
- compounds
- methods
- present disclosure
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 229940124785 KRAS inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160431P | 2021-03-12 | 2021-03-12 | |
| US202163173021P | 2021-04-09 | 2021-04-09 | |
| US202163220386P | 2021-07-09 | 2021-07-09 | |
| US202163236497P | 2021-08-24 | 2021-08-24 | |
| PCT/US2022/020239 WO2022192794A1 (en) | 2021-03-12 | 2022-03-14 | Kras g12d inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010430A true MX2023010430A (es) | 2023-09-12 |
Family
ID=81213567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010430A MX2023010430A (es) | 2021-03-12 | 2022-03-14 | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240317769A1 (https=) |
| EP (1) | EP4305038B1 (https=) |
| JP (1) | JP2024510606A (https=) |
| KR (1) | KR20230169967A (https=) |
| AU (1) | AU2022232523A1 (https=) |
| BR (1) | BR112023017763A2 (https=) |
| CA (1) | CA3210053A1 (https=) |
| ES (1) | ES3013592T3 (https=) |
| IL (1) | IL305568A (https=) |
| MX (1) | MX2023010430A (https=) |
| WO (1) | WO2022192794A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2022068921A1 (zh) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| CN115181106B (zh) * | 2021-04-07 | 2024-04-05 | 药雅科技(上海)有限公司 | 喹唑啉类krasg12d突变蛋白抑制剂的制备及其应用 |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| EP4363412A4 (en) * | 2021-06-30 | 2025-05-14 | Dana-Farber Cancer Institute, Inc. | Small-molecule inhibitors of the KRAS G12D mutant |
| WO2023114733A1 (en) * | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| EP4371991A4 (en) * | 2022-01-21 | 2025-02-26 | Usynova Pharmaceuticals Ltd. | Benzopyrimidine compounds and use thereof |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| CN118344386A (zh) * | 2023-01-13 | 2024-07-16 | 苏州泽璟生物制药股份有限公司 | 取代桥环类抑制剂及其制备方法和应用 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202416976A (zh) * | 2022-09-16 | 2024-05-01 | 大陸商南京明德新藥研發有限公司 | 含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物 |
| WO2024061365A1 (zh) * | 2022-09-22 | 2024-03-28 | 成都奥睿药业有限公司 | 嘧啶并环类化合物及其制备方法与用途 |
| JP2025534419A (ja) * | 2022-09-30 | 2025-10-15 | トラスヴェダ リミテッド | Ｋｒａｓ変異腫瘍に対する抗腫瘍活性を有する化合物 |
| EP4631942A1 (en) | 2022-10-21 | 2025-10-15 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Pan-kras degrading agent, and preparation method therefor and use thereof |
| JP2025536369A (ja) | 2022-10-21 | 2025-11-05 | リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド | Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用 |
| CN117263959A (zh) * | 2022-10-24 | 2023-12-22 | 药雅科技(上海)有限公司 | 芳香类kras突变蛋白抑制剂的制备及其应用 |
| WO2024092420A1 (zh) * | 2022-10-31 | 2024-05-10 | 上海皓元医药股份有限公司 | 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024186680A1 (en) * | 2023-03-03 | 2024-09-12 | Frontier Medicines Corporation | Methods for preparing pyrrolizidine compounds |
| CN117903192A (zh) * | 2023-03-12 | 2024-04-19 | 上海相辉医药科技有限公司 | 一种3-甲氧基异喹啉化合物中间体的制备方法 |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| WO2024215862A2 (en) * | 2023-04-12 | 2024-10-17 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as nras inhibitors |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| WO2024227091A1 (en) * | 2023-04-26 | 2024-10-31 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Diazabicyclooctane inhibitors of kras (g12d) and uses |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN121100120A (zh) * | 2023-05-07 | 2025-12-09 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR102738924B1 (ko) * | 2023-12-26 | 2024-12-06 | 주식회사 베노바이오 | Kras g12d 변이가 존재하는 암 치료를 위한 신규한 화합물 및 이를 이용한 암의 예방 또는 치료용 조성물 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10745385B2 (en) * | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| WO2021031952A1 (zh) * | 2019-08-16 | 2021-02-25 | 劲方医药科技(上海)有限公司 | 氧代六元环并嘧啶类化合物，其制法与医药上的用途 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| WO2022061251A1 (en) * | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| KR20230136636A (ko) * | 2021-02-09 | 2023-09-26 | 메드샤인 디스커버리 아이엔씨. | 피리미딘 방향족 환 화합물 |
| BR112023016299A2 (pt) * | 2021-02-16 | 2023-11-28 | L Livermore Nat Security Llc | Composições e métodos para inibir kras |
-
2022
- 2022-03-14 MX MX2023010430A patent/MX2023010430A/es unknown
- 2022-03-14 IL IL305568A patent/IL305568A/en unknown
- 2022-03-14 US US18/550,234 patent/US20240317769A1/en active Pending
- 2022-03-14 EP EP22714667.7A patent/EP4305038B1/en active Active
- 2022-03-14 ES ES22714667T patent/ES3013592T3/es active Active
- 2022-03-14 BR BR112023017763A patent/BR112023017763A2/pt unknown
- 2022-03-14 JP JP2023555666A patent/JP2024510606A/ja active Pending
- 2022-03-14 AU AU2022232523A patent/AU2022232523A1/en active Pending
- 2022-03-14 CA CA3210053A patent/CA3210053A1/en active Pending
- 2022-03-14 KR KR1020237034229A patent/KR20230169967A/ko active Pending
- 2022-03-14 WO PCT/US2022/020239 patent/WO2022192794A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES3013592T3 (en) | 2025-04-14 |
| CA3210053A1 (en) | 2022-09-15 |
| US20240317769A1 (en) | 2024-09-26 |
| WO2022192794A1 (en) | 2022-09-15 |
| BR112023017763A2 (pt) | 2023-10-03 |
| AU2022232523A1 (en) | 2023-11-16 |
| JP2024510606A (ja) | 2024-03-08 |
| EP4305038B1 (en) | 2025-01-29 |
| IL305568A (en) | 2023-10-01 |
| KR20230169967A (ko) | 2023-12-18 |
| EP4305038A1 (en) | 2024-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023010430A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). | |
| MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
| MX2025001648A (es) | Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras) | |
| MX2025015502A (es) | Inhibidores del oncogén de sarcoma de rata de kirsten (kras) | |
| MX2024005228A (es) | Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras). | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| MX2023011856A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. | |
| ZA202202559B (en) | Kras g12c inhibitors and methods of using the same | |
| MX2020012731A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| MX2021005700A (es) | Inhibidores de kras g12c y metodos de uso de los mismos. | |
| MX2022005726A (es) | Sintesis mejorada del compuesto inhibidor de g12c de kras. | |
| MX2020010836A (es) | Inhibidores de kras g12c y métodos para su uso. | |
| MX2020011582A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| MX2020002502A (es) | Inhibidores de kras g12c y metodos para utilizarlos. | |
| CR20190478A (es) | Inhibidores de pd-1/pd-l1 | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| MX2023004802A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| MX2023008701A (es) | Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38). | |
| WO2022240971A3 (en) | Kras g12d inhibitors and uses thereof | |
| MX393711B (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres |